Results for tag: "Gemcitabine Hydrochloride"

=== Gemcitabine Hydrochloride in the Lung Cancer Drugs Market === Within the realm of lung cancer therapeutics, gemcitabine hydrochloride stands as a notable chemotherapeutic agent. It is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC), one of the two main types of lung cancer, and is also employed in various regimens for other types of malignancies. The drug functions by inhibiting DNA synthesis, leading to cell death, particularly in actively dividing cells, such as cancer cells. Gemcitabine may be utilized alone or in combination with other agents such as platinum-based drugs, to enhance efficacy. Its market presence is sustained by its established role in standard lung cancer treatment protocols and ongoing clinical studies evaluating its effectiveness in various treatment combinations and sequences. Its administration and dosage are typically tailored to individual patient factors, including type and stage of cancer, as well as overall health status. ### Companies in the Market ### Several pharmaceutical companies are involved in manufacturing and distributing gemcitabine hydrochloride. Some established players in the market include Eli Lilly and Company, Teva Pharmaceutical Industries, Fresenius Kabi Oncology, Pfizer Inc., Sun Pharmaceutical Industries, and Mylan N.V. These companies are engaged in providing the medication to healthcare providers and patients, ensuring the drug's accessibility for cancer treatment. Show Less Read more